Replimune's RP1 wins 10-3 FDA advisory committee vote for advanced melanoma
An FDA advisory committee voted 10-3 that IGNYTE study efficacy results for Replimune's RP1 in advanced melanoma are evaluable and clinically meaningful. The favorable panel outcome de-risks the path toward a PDUFA decision and reduces the odds of an outright rejection or request for another trial.
STOCK PHOTO · MARK STEBNICKIThe story
Replimune announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10 to 3 that efficacy results from the company's IGNYTE study are evaluable and clinically meaningful for RP1, its oncolytic immunotherapy candidate in advanced melanoma. Advisory committee votes are not binding on the FDA, but a supportive vote of this margin is generally read as a positive signal ahead of a formal regulatory decision.
This matters because RP1 is Replimune's lead pipeline asset, and the company's near-term valuation is heavily tied to its regulatory outcome. A negative panel vote would have raised serious doubt about accelerated approval prospects and likely forced additional costly trials; a positive vote instead keeps the current approval pathway intact based on the IGNYTE dataset.
The second-order setup here is straightforward: markets tend to reward strong adcom votes with a sharp initial pop, since binary regulatory risk has been meaningfully reduced, even though the FDA still has to issue its own decision. The tension going forward is between the market pricing in near-certain approval now, versus the fact that the FDA has occasionally diverged from advisory committee recommendations, and commercial launch execution risk in melanoma remains untested. Watch for the actual FDA decision date and any commentary from the agency reflecting on the committee's rationale, as well as how the stock's reaction settles once the initial move fades.
Our read · Thu, Jul 30
REPL's regulatory setup for RP1 in advanced melanoma just cleared a major hurdle with a 10-3 favorable adcom vote, raising the question of how much of that reduced risk is already priced in versus what remains for the formal FDA decision.
Why. A 10-3 favorable adcom vote on efficacy evaluability materially reduces the probability of an FDA rejection or additional trial requirement, which is the single largest overhang on RP1 and Replimune's valuation. Adcom votes of this margin have historically preceded approval more often than not, supporting a near-term long bias into the actual FDA decision.
Both cases
What could change this view: The FDA is not bound by the adcom vote and could still request additional data or issue a complete response letter, and any post-vote rally could reverse sharply if that risk resurfaces or if the initial pop already fully priced in the good news.
Who reported it · 1
Keep reading
Latest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeGerman producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by GlobeNewswire as Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →